[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-393902-105":59,"doc-detail-393902-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","alzheimer-disease-primer","Alzheimer disease - Primer","","Alzheimer disease (AD) is biologically defined by β-amyloid-containing plaques and tau-containing neurofibrillary tangles. It presents as an amnestic cognitive impairment in typical cases, while rarer variants can show non-amnestic impairment. AD is a common midlife and late-life cause of cognitive impairment, with clinical impact shaped by comorbid neurodegenerative and cerebrovascular conditions. The Primer frames AD biology as arising from loss of synaptic homeostasis and endosomal/lysosomal clearance dysfunction, where Aβ and tau precursors, aggregates, and post-translational products are central; current therapeutic efforts still have difficulty finding targets that substantially alter the clinical course.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/alzheimer-disease-primer/393902/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/alzheimer-disease-primer/393902.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-26",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How is Alzheimer disease biologically defined?","Question",{"text":113,"@type":114},"Alzheimer disease is defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What cognitive impairments characterize Alzheimer disease?",{"text":118,"@type":114},"Typical presentation involves amnestic cognitive impairment, while less common variants can cause non-amnestic cognitive impairment.",{"name":120,"@type":111,"acceptedAnswer":121},"What biological framework does the Primer propose for Alzheimer disease?",{"text":122,"@type":114},"It proposes that AD results from a complex interplay of loss of synaptic homeostasis and dysfunction in highly interrelated endosomal/lysosomal clearance pathways involving Aβ and tau species and their post-translationally modified products.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},393902,1790816240,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Nat Rev Dis Primers. Author manuscript; available in PMC 2021 November 08. |\n| --- | --- |\n\nPublished in final edited form as:  \nNat Rev Dis Primers. ; 7(1): 33. doi:10.1038/s41572-021-00269-y.  \nAlzheimer disease  \nDavid S. Knopman 1 , Helene Amieva2 , Ronald C. Petersen 1 , Gäel Chételat3 , David M. Holtzman4 , Bradley T. Hyman5 , Ralph A. Nixon6,7 , David T. Jones 1  \n1 Department of Neurology, Mayo Clinic, Rochester, MN, USA.  \n2 Inserm U1219 Bordeaux Population Health Center, University of Bordeaux, Bordeaux, France.  \n3 Normandie Univ, UNICAEN, INSERM, U1237, PhIND “Physiopathology and Imaging of Neurological Disorders”, Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.  \n4 Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.  \n5 Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.  \n6 Departments of Psychiatry and Cell Biology, New York University Langone Medical Center, New York University, New York, NY, USA.  \n7 NYU Neuroscience Institute, New York University Langone Medical Center, New York University, New York, NY, USA.  \n[knopman@mayo.edu](knopman@mayo.edu) .  \nAuthor contributions  \nIntroduction (D.S.K.); Epidemiology (H.A.); Mechanisms/pathophysiology (D.T.J., R.A.N., B.T.H. and D.M.H.); Diagnosis, screening and prevention (G.C., R.C.P. and D.S.K.); Management (R.C.P. and D.S.K.); Quality of life (D.S.K.); Outlook (D.S.K.); Overview of Primer (D.S.K.) .  \nCompeting interests  \nD.S.K. served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for atau therapeutic for Biogen but receives no personal compensation. He is a site investigator in a Biogen aducanumab trial. He isan investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock, Roche and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH. G.C. serves on the Scientific Advisory Board of the Fondation Vaincre Alzheimer but receives no personal compensation. She receives personal fees from Fondation d’entreprise MMA des Entrepreneurs du Futur and from Fondation Alzheimer as she serves in the Operational Committee. She receives research support from European Union Horizon 2020 research and innovation programme (grant agreement number 667696), Inserm, Fondation d’entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, Région Normandie, Association France Alzheimer et maladies apparentées and Fondation Vaincre Alzheimer. R.C.P. is a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc. and Eisai, Inc., has given educational lectures for GE Healthcare, receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), UpToDate, and receives research support from the NIH. B.T.H. has a family member who works at Novartis and owns stock in Novartis; he serves on the SAB of Dewpoint and owns stock. He serves on a scientific advisory board or is a consultant for Biogen, Novartis, Cell Signalling, the US Dept of Justice, Takeda, Vigil, W20 group and Seer. His laboratory is supported by sponsored research agreements with Abbvie, F Prim, and research grants from the National Institutes of Health, Cure Alzheimer’s Fund, Tau Consortium, Brightfocus and the JPB Foundation. H.A. serves on the Scientific Advisory Board of the Observatoire des Mémoires but receives no personal compensation. She receives research support from Spoelberch Foundation, Association France Alzheimer et maladies apparentées, the Regional Health Agency of Aquitaine and National Research Agency.  \nD.M.H. reports being a Co-founder for C2N Diagnostics LLC and participating in scientific advisory boards/consulting for","cbCaispgT0reMFmB","https://ap.wps.com/l/cbCaispgT0reMFmB","pdf",2049417,47,"English","# Introduction\n# Epidemiology\n# Mechanisms/pathophysiology\n# Diagnosis, screening and prevention\n# Management\n# Quality of life\n# Outlook\n# Overview of Primer","[{\"question\":\"How is Alzheimer disease biologically defined?\",\"answer\":\"Alzheimer disease is defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles.\"},{\"question\":\"What cognitive impairments characterize Alzheimer disease?\",\"answer\":\"Typical presentation involves amnestic cognitive impairment, while less common variants can cause non-amnestic cognitive impairment.\"},{\"question\":\"What biological framework does the Primer propose for Alzheimer disease?\",\"answer\":\"It proposes that AD results from a complex interplay of loss of synaptic homeostasis and dysfunction in highly interrelated endosomal/lysosomal clearance pathways involving Aβ and tau species and their post-translationally modified products.\"}]","Alzheimer disease - Primer | PDF",1790395950,118]